AMARANTUS BIOSCIENCE HOLDINGS IN (OTCMKTS:AMBS) Reports Decline in Sellers; Strong Momentum for Longs

November 14, 2017 - By Vivian Park

The stock of AMARANTUS BIOSCIENCE HOLDINGS IN (OTCMKTS:AMBS) registered a decrease of 96% in short interest. AMBS’s total short interest was 100 shares in November as published by FINRA. Its down 96% from 2,500 shares, reported previously.

About 254,132 shares traded or 99.36% up from the average. Amarantus Bioscience Holdings Inc (OTCMKTS:AMBS) has 0.00% since November 14, 2016 and is . It has underperformed by 16.70% the S&P500.

Amarantus Bioscience Holdings, Inc. is a biopharmaceutical holding company. The company has market cap of $1.61 million. The Firm has approximately three operating divisions: the diagnostics division, the therapeutics division and the drug discovery division. It currently has negative earnings. It owns licenses to various product candidates in the therapeutic and diagnostic sectors of the life sciences industry.

More notable recent Amarantus Bioscience Holdings Inc (OTCMKTS:AMBS) news were published by: Usmarketsdaily.com which released: “AMARANTUS BIOSCIENCE HOLDINGS, INC. (OTCBB:AMBS) Pays $2.3 Million In Final …” on March 06, 2015, also Prnewswire.com with their article: “Regenicin Enters Into Asset Purchase Agreement with Amarantus Bioscience …” published on November 19, 2014, Seekingalpha.com published: “Amarantus’ LymPro Could Be A Game-Changer For Alzheimer’s Diagnosis” on April 17, 2013. More interesting news about Amarantus Bioscience Holdings Inc (OTCMKTS:AMBS) were released by: Marketwatch.com and their article: “0.0212” published on June 30, 2011 as well as Globenewswire.com‘s news article titled: “Amarantus Effects Capital Restructuring in Anticipation of National Exchange …” with publication date: May 22, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.